A research team at Massachusetts Institute of Technology (MIT) developed a capsule about the size of a blueberry that holds a tiny needle that, after being swallowed, injects insulin into the stomach.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Gene therapy company UniQure NV said on Friday the company’s experimental treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.
Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.
Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.
New York City-based HiberCell launched with a $60.75 million Series A funding, led by ARCH Venture Partners.
GlaxoSmithKline is significantly reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company made some cuts to the product pipeline, including six in GSK’s 2018 year-end report.
Just one in 20 U.S. children and teens gets the amount of sleep, exercise and screen time that doctors recommend for optimal health, a new study suggests.
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company and Incyte Corporation announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Accelerated Evolution Biotechnologies’s claims to have found a cure for cancer are, appropriately, being met with global skepticism.